Abstract:Fibroblast growth factor receptors (FGFRs) are a family of cell surface receptors that bind to fibroblast growth factor (FGF) and mediate various cellular functions (translocating proteins, tissue repair, cell proliferation, development, and differentiation) through complex signaling pathways. The FGFR1 growth receptor is essential in the pathogenesis of numerous malignancies, including but not limited to breast cancer, bladder cancer, hepatocellular carcinoma (HCC), and cholangiocarcinoma. The higher levels of FGFR1 expression on the surface of cancer cells cause overly active signaling, which leads to rapid cell proliferation, resulting in a high spread of cancer cells. The kinases that FGFR1 activates migrate across the cell nucleus, activating genes and kinase proteins necessary for the growth and survival of cancerous cells. Therefore, FGFR1 targeting shows therapeutic promise in some diseases, including cancer. Inhibitors of FGFR1s are being developed and studied for their potential to block aberrant FGFR1 signaling and inhibit cancer growth. Since the discovery of new FGFR1 inhibitors in the laboratory is difficult, expensive, time-consuming, and labor-intensive, only a small number of FGFR1 inhibitors have been approved by the FDA for use in the treatment of cancer. To accelerate drug discovery by efficiently exploring the vast chemical space, and identifying potential candidates with higher accuracy and reduced cost, we developed artificial intelligence (AI)-based prediction models for FGFR1 inhibitors using a dataset of 2356 chemical compounds. Four machine learning (ML) algorithms (SVM, RF, k-NN, and ANN) were used to train different prediction models based on molecular descriptors (1D and 2D, with and without molecular fingerprints). Among all trained models, the random forest (RF)-based prediction model achieved the highest accuracy on the training (98.9%), test (89.8%), and external test (90.3%) datasets. The developed inhibitor prediction model (FGFR1Pred) provides a valuable tool for identifying potential FGFR1 inhibitors, expediting the drug discovery process and ultimately facilitating the development of new therapeutics. The model is made available at https://github.com/PGlab-NIPER/FGFR1Pred.git.

Toward The Prediction Of Fbpase Inhibitory Activity Using Chemoinformatic Methods

In Silico Identification of Structure Requirement for Novel Thiazole and Oxazole Derivatives as Potent Fructose 1,6-Bisphosphatase Inhibitors

Exploration of N-Arylsulfonyl-indole-2-carboxamide Derivatives as Novel Fructose-1,6-bisphosphatase Inhibitors by Molecular Simulation

3D-QSAR Studies and Molecular Docking on [5-(4-amino-1h-benzoimidazol-2-yl)-furan-2-yl]-phosphonic Acid Derivatives As Fructose-1,6-biphophatase Inhibitors

Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes

Molecular Modeling Studies on Phosphonic Acid-Containing Thiazole Derivatives: Design for Fructose-1,6-bisphosphatase Inhibitors

Predicted Par1 Inhibitors from Multiple Computational Methods

Improved Prediction Of Drug-Target Interactions Based On Ensemble Learning With Fuzzy Local Ternary Pattern

Discovery of novel fructose-1,6-bisphosphatase inhibitors bearing benzimidazole scaffold using a dual-ligand molecular docking model

ChemInform Abstract: Design, Synthesis and Biological Activity Evaluation of 2,5‐diphenyl‐1,3,4‐oxadiazole Derivatives As Novel Inhibitors of Fructose‐1,6‐bisphosphatase.

Discover Potential Inhibitors for PFKFB3 Using 3D-QSAR, Virtual Screening, Molecular Docking and Molecular Dynamics Simulation.

Synthesis and Structure-Activity Relationship of Non-Phosphorus-based Fructose-1,6-bisphosphatase Inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles.

FGFR1Pred: an artificial intelligence-based model for predicting fibroblast growth factor receptor 1 inhibitor

Computational Bioactivity Fingerprint Similarities To Navigate the Discovery of Novel Scaffolds

Pharmacophore-Based Virtual Screening and Experimental Validation of Novel Inhibitors against Cyanobacterial Fructose-1, 6-/Sedoheptulose-1, 7-bisphosphatase.

Prediction Of Pkc Theta Inhibitory Activity Using The Random Forest Algorithm

Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues.

In Silico Prediction of Androgenic and Nonandrogenic Compounds Using Random Forest

Predicting FFAR4 agonists using structure-based machine learning approach based on molecular fingerprints

Pharmacophore Modeling and Virtual Screening for the Discovery of New Fatty Acid Amide Hydrolase Inhibitors

Exploiting Structural Information in Patent Specifications for Key Compound Prediction